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RESULTS: In spite of the same quality of life score at the ﬁ rst session of chemotherapy 
(74.5 out of 100), after ﬁ nishing the chemotherapy cycle, patients in TAC arm had 
the lower score of QOL (64 in TAC vs. 68 in FAC) and higher range of toxicity and 
their medical costs were higher as well (the average costs in TAC was 391,176,968.2 
Rials vs. 2,427,775.2 in FAC). ICER was negative that showed the dominant result 
for FAC comparing with TAC. CONCLUSIONS: It seems that because of the short 
horizon of the study, TAC regimen had the worse impact on the patient’s quality of 
life during the chemotherapy cycle because of more side effects than FAC. It is believed 
that there is need for other studies with longer time horizons and speciﬁ c attention to 
the effects of these treatments on survival and quality of life.
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OBJECTIVES: Breast cancer is known to be one of the leading causes of death among 
the female population. Preventive measures may provide an economic and outcome 
advantage by reducing treatment costs and increasing survival. The objective of this 
study was to evaluate the cost-effectiveness of a breast cancer vaccine versus current 
standard treatments. METHODS: TreeAge software was used to calculate the cost-
effectiveness. a decision tree was constructed for different probabilities of success and 
failure for the vaccine versus standard treatment. Costs and outcomes (life-years saved) 
ranges were obtained from published clinical trials. The vaccine effectiveness was 
projected from animal studies, with human clinical trials expected within a year. The 
range of effectiveness of the vaccine was considered between 30% and 90% with a 
baseline at 80%. The costs included for standard treatments ranged from $20,000 to 
$45,000 and the cost of the vaccine was assumed at $450 for three doses; therefore, 
the cost for vaccine ranged from $300 to $2000 depending on the number of doses. 
The incremental cost-effectiveness ratios were calculated from the range of costs and 
outcomes. Sensitivity analyses were performed to determine the robustness of the 
ﬁ ndings. RESULTS: Vaccination was found to be a potentially cost-effectiveness 
option with an ICER of 2384.146 relative to standard treatment. The incremental 
effectiveness was 8.2 life-years saved. The highest cost-effectiveness of the vaccine was 
at 90% success and a cost of not more than $1000 per individual. Sensitivity analyses 
indicated that the vaccine remained cost-effective over the range of model parameters. 
CONCLUSIONS: The breast cancer vaccine was projected to be the most cost-
effective treatment option in this analysis. It is expected that better screening for breast 
cancer vaccine patient candidates will be available in the future.
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OBJECTIVES: For the ﬁ rst time in a modern Russian economic conditions, it has been 
made pharmacoeconomics trial (PE) uses Russian generic of paclitaxel (Paclitaxel-Lens 
[PL]) in comparison with original drug (Taxol (T)) at chemotherapy (ChT) in a 
monomode for 2nd line of metastatic breast cancer (MBC) in real clinical practice. 
METHODS: It has been provided retrospective comparative nonrandomized clinical 
trial which have been included 70 patients for 35 patients of each group (PL or T) 
after analysis of 148 case records. RESULTS: At the analysis of effectively treatment 
MBC in group of the patients who have received T, the partial remission (PR, 28.5% 
against 10%) statistically signiﬁ cantly has been more often reached. At the analysis 
of safety, it has been shown that in group of the patients who have received PL, 
statistically signiﬁ cantly has been more often ﬁ xed hepatotoxicity (23.3% against 
3.8%) and an anemia (19.2% against 3.5%). In group of the patients who have 
received T, statistically signiﬁ cantly has been more often ﬁ xed arthralgia/ myalgia 
(29.8% against 0%). Total direct costs (DC) in group of patients with T also there 
were above, than in group of PL, namely $10,727 and $9765 accordingly. Calculation 
of efﬁ ciency of expenses has shown that treatment of MBC by T more expensive and 
more effective, than treatment by PL. CONCLUSIONS: Thus, as a result of research, 
it has been established that: 1) Applying of T was more (from 7% to 11%) expensive, 
than PL, but gave the PR is much more often; 2) The alternative scenario and the 
sensitivity analysis shown to choose conditions when application of compared drugs 
will be economically more expedient; and 3) Thus, it is necessary to take into consid-
eration, what application of PL was more often accompanied by hepatotoxicity and 
anemia, like arthralgia/ myalgia after using of T.
PCN91
BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. 
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OBJECTIVES: To determine and compare the cost-effectiveness of Bev + Pac + Car 
versus Pem + Cis regimens in the treatment of patients with adenocarcinoma non-
squamous NSCLC from a Polish Public Payer’s perspective. METHODS: Efﬁ cacy and 
safety of 15 mg of bevacizumab + 200 mg/m2 of paclitaxel + 6 mg/mL/min of carbo-
platin versus 500 mg/m2 of pemetrexed and 75 mg/m2 of cisplatin was assessed based 
on a systematic review performed for both therapies according to evidence-based 
medicine principles. A cost-effectiveness analysis was performed with a lifetime (5 
years) horizon and the National Health Fund perspective. a three state (progression-
free, progression, death) Markov model was developed. Costs of 1st and 2nd line 
therapy, administration and monitoring, adverse events treatment, and palliative care 
were included. Sensitivity analyses testing the inﬂ uence of length of time horizon, 
probability of progression, utilities, discounting rates, cisplatin dose, and the length 
and costs of 2nd line therapy were performed. RESULTS: Bev + Pac + Car results in 
0.21 life-years gained per patient when compared to Pem + Cis in the treatment of 
patients with adenocarcinoma non-squamous NSCLC. The additional cost per patient 
was 18,840 pln (1 EURO = 4.1PLN) over patient’s lifetime when Bev + Pac + Car 
was used instead of Pem + Cis regimen. The incremental cost-effectiveness ratio (ICER) 
was at an acceptable 91,216 pln. The sensitivity analyses demonstrated that the dura-
tion of 2nd line treatment (assumption of 2nd line treatment continuation for more 
than six cycles) considerably inﬂ uenced the ICER (1,198 pln). Other sensitivity analy-
ses conﬁ rmed the base-case results, proving conclusions’ robustness. CONCLUSIONS: 
Based on this modeling analysis, 1st line Bev + Pac + Car therapy is a clinically superior 
and cost-effective treatment for patients with adenocarcinoma non-squamous NSCLC 
when compared to chemotherapies such as Pem + Cis.
PCN92
PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC 
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The problem of original drugs substitution on generics presents in the Russian clinical 
practice due to rational expenditures allocation. Pharmaceutical bioequivalence of 
generic should be conﬁ rmed by therapeutic one. Only after such kind of conﬁ rmation, 
the mentioned substitution could be made in different segments of doctors’ practice 
especially in anticancer chemotherapy. OBJECTIVES: To evaluate the clinical-eco-
nomic interchangeability of the original oxaliplatin Eloxatine (EL) and local generic 
Exorum (EX) in the chemotherapy of mCCR. METHODS: The retrospective clinical-
economic analysis of FOLFOX scheme for chemotherapy of mCCR with EL and EX 
in the real practice has been performed. Fifty case histories (23 with using of EL, 
27—EX, was used nomogram of Altman’s) were studied. The calculation of direct 
cost and cost-effectiveness ratio (CER) based on “partial regress + stabilization” 
parameter no less than 80% has been performed. RESULTS: For achievement of equal 
efﬁ cacy EL had less number of chemotherapy cycles and total dosage compared with 
EX (5,0 and 7,3; 670 mg and 900 mg, respectively). Adverse effects were more fre-
quent in EX versus EL (59 and 38, respectively) and caused additional costs and 
prolonged hospitalization (9 days/patient compared to EL group). The utilitarian EX 
program cost per patient was less compared to EL by 7,7%. In the same time, CER 
calculated with total costs due to side effects treatment was practically equal (differ-
ence is 1,6% only). Cost prognosis for equal efﬁ cacy results with EL using is less by 
28,6% versus EX. The alternative scenario has conﬁ rmed the cinical-economic added 
value of EL. CONCLUSIONS: The change of original EL for generic EX in FOLFOX 
scheme for mCCR has no economic advantages. EL substitution leads to increased 
number of chemotherapy cycles, higher dose of oxaliplatin, higher rate of adverse 
effects, and higher costs.
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COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE + 
OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS 
ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE 
BRAZILIAN PRIVATE PAYER PERSPECTIVE
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BACKGROUND: Colorectal cancer is the third leading cancer worldwide (INCA) 
with nearly 1.2 million cases and about 630,000 deaths expected in 2007 (ACS 2007). 
In Brazil, it is estimated 28,110 new cases in 2010 (INCA 2010). For patients with 
stage III colon cancer, the beneﬁ ts from ﬂ uorouracil (5-FU)-based adjuvant chemo-
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therapy are well established and the combination regimens including a ﬂ uoropyrimi-
dine + oxaliplatin are the current standard of care. OBJECTIVES: To compare costs 
of XELOX with FOLFOX-4 as adjuvant treatment for stage III colon cancer under 
Brazilian private payer perspective. METHODS: Both regimens demonstrated to sig-
niﬁ cantly improve disease-free survival when compared to 5-FU/LV for adjuvant 
treatment of stage III colon cancer (MOSAIC and XELOXA trials). In the absence of 
head-to-head trials comparing both regimens, an indirect comparison using Butcher 
approach (Butcher 1997) was conducted. No difference was found regarding efﬁ cacy 
of regimens (XELOX vs. FOLFOX-4 in disease-free survival: HR 1.03, 95% CI 0.81, 
1.29); therefore, a cost-minimization analysis was used. a modiﬁ ed Delphi panel 
identiﬁ ed local practices to manage severe adverse events (SAEs) of each scheme. Only 
direct costs were considered for a patient with 1.7 m2. Drug prices were obtained from 
ofﬁ cial public sources (Kairos Magazine, April 2010) and administration costs from 
medical society physicians fee list (CBHPM2008, v.5). Time horizon was 6 months 
according to clinical recommendations: eight cycles for XELOX and 12 for FOLFOX-
4. Discounting was not applied. RESULTS: XELOX is less costly than FOLFOX-4 
($Brz49,862 vs. $Brz57,846). XELOX has higher acquisition costs which is offset by 
savings in medical resource utilization. Mean acquisition costs for XELOX were 
R$4185 higher than with FOLFOX-4, but costs to treat SAEs and administration costs 
were $Brz12,169 higher for FOLFOX-4. One-way sensitivity analysis conﬁ rmed the 
robustness of results. CONCLUSIONS: Findings suggest XELOX as a cost-saving 
therapy for the adjuvant setting under the private payer perspective in Brazil when 
compared to FOLFOX-4.
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OBJECTIVES: FOLFOX4 has been the chemotherapy of choice for patients with stage 
III colon cancer. Recently, the international NO16968 study reported results conﬁ rm-
ing the efﬁ cacy of XELOX in this setting, and evidence suggests that both regimens 
have at least equivalent efﬁ cacy. Therefore, medical and societal resource utilization 
are important factors for providers, patients, and payers. The objective of this analysis 
was to compare total costs required to treat an average aCC patient with either 
XELOX or FOLFOX4 in Switzerland. METHODS: In the absence of a direct com-
parison, detailed medical resource utilization (MRU) data collected for XELOX from 
study NO16,968 (aCC) and for FOLFOX4 from study NO16,966 (metastatic colorec-
tal cancer) were analyzed. The FOLFOX4 regimens are identical in both indications; 
therefore, MRU data from NO16,966 were considered valid proxies. In addition to 
direct MRU (chemotherapy, hospitalizations due to adverse events [AEs], ambulatory 
encounters, AE medication, and central venous access [CVA] placements), patient time 
and travel costs for hospitalizations, ambulatory encounters, and drug administration 
were estimated. Unit costs were derived from ofﬁ cial tariffs (Spezialitätenliste, Tarmed 
2010 for drug costs and physician services), ofﬁ cial statistics (hospital cost, mean 
hourly salary) and tax guidelines (travel costs). Total costs while on treatment (24 
weeks) for an average patient with aCC were compared. RESULTS: On average, 
XELOX saved CHF 11,471 per patient versus FOLFOX4. CHF 8883 resulted from 
savings in direct costs, mainly driven by savings in drug administration (CHF 9312) 
and CVA placements (CHF 1730). Savings in patient time and travel costs amounted 
to CHF 2588. CONCLUSIONS: XELOX appears to be cost-saving versus FOLFOX4 
in aCC from both a Swiss health-care system and the societal perspective, assuming 
equivalent efﬁ cacy for the two regimens. Considering the high incidence of colon 
cancer in Switzerland, substantial overall savings may be realized by routine use of 
XELOX in this indication.
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A MARKOV MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF 
OMACETAXINE IN CHRONIC MYELOID LEUKEMIA
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OBJECTIVES: In patients with chronic myeloid leukemia (CML), ﬁ rst-line treatment 
with imatinib therapy is beneﬁ cial. In cases of imatinib failure, second-generation 
tyrosine kinase inhibitors (TKIs) are recommended. Omacetaxine has a novel mode 
of action and acts independently of TKIs; thus, it may have therapeutic advantages 
for patients who have developed resistance to TKI therapy and have no available 
treatment options. The objective was to develop a health economic model to estimate 
the cost-effectiveness of omacetaxine in the treatment of CML. METHODS: A cost-
utility Markov model was developed to capture the progression of CML and treatment 
effects. The model was developed from the perspective of the French health-care 
system. Patients entered the model treated either with omacetaxine or standard care, 
in one of three phases: chronic, accelerated, or blast phase, having failed on imatinib 
therapy (through resistance or intolerance). Patients then moved to states of response, 
no response, or death. Survival estimates for nonresponding and responding patients 
were taken from studies 202 and 203. These were extrapolated using parametric curve 
ﬁ ts to estimate survival beyond the end of the trial. Resource use was based on the 
trial and from the expert opinion of a panel of French clinicians. Unit costs and utilities 
were elicited from the literature. One-way and probabilistic sensitivity analyses (PSA) 
were performed. RESULTS: The deterministic results demonstrated that treatment 
with omacetaxine is cost-effective at a threshold of c30,000. Sensitivity analysis 
showed that results were most sensitive to cost of omacetaxine, utility score, and 
survival beneﬁ t. PSA results showed that the model was sufﬁ ciently robust to param-
eter uncertainty. CONCLUSIONS: The analysis demonstrated that omacetaxine is 
cost-effective in the treatment of CML patients who are resistant to TKI therapy and 
have no available treatment options.
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TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL 
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OBJECTIVES: Paclitaxel albumin (P-A, Abraxane®) is nanoparticle albumin-bound 
paclitaxel formulated without use of irritant solvents that are responsible for many of 
the hypersensitivity and dose-limiting adverse events (AEs). Previous research has 
compared its cost-effectiveness to solvent-based paclitaxel (S-P) and docetaxel (DOC) 
in a cohort of patients with mixed treatment history. This study examined P-A’s cost-
effectiveness for pretreated MBC, the population speciﬁ ed in the European license. 
METHODS: A Markov model with progression-free, progressed, and mortality states 
was developed to estimate costs and outcomes over 5 years from a UK NHS perspec-
tive. Included from published sources were the costs at 2009 prices of drugs, admin-
istration, AEs, and supportive care. Published utility weights were applied to health 
states to estimate the impact of response, disease progression, and AEs on quality-
adjusted life-years (QALYs). Clinical data for pretreated patients receiving P-A 
260 mg/m2 3-weekly (q3w) and S-P 175 mg/m2 q3w were from Gradishar (2005). 
Using Bucher’s methods, an indirect comparison with Jones (2005) provided estimates 
of clinical parameters for DOC 100 mg/m2 q3w. Weibull extrapolations of survival 
data generated transition probabilities. RESULTS: Compared to S-P, P-A achieved an 
extra 0.164 QALYs, 0.263 life-years, and incurred additional costs of £4,137 per 
patient treated. This translated to an incremental cost-effectiveness ratio of £25,209/
QALY. P-A saved £697 when compared to DOC, with a marginal QALY gain of 
0.0037 and no life-expectancy divergence. Probabilistic sensitivity analysis versus 
DOC indicated a 61% likelihood of P-A satisfying a willingness-to-pay threshold of 
£30,000/QALY. Both comparisons were sensitive to drug costs and survival estimates. 
Accounting for potential drug wastage did not inﬂ uence interpretation of results from 
either comparison. CONCLUSIONS: The model found that P-A gave better outcomes 
than S-P or DOC and was cost-effective compared to both interventions. This 
depended upon greater efﬁ cacy than S-P and a more favorable safety proﬁ le than 
DOC.
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ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE 
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THE UK NATIONAL HEALTH SERVICE (NHS)
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OBJECTIVES: To assess the cost-effectiveness of trastuzumab/anastrozole compared 
to lapatinib/letrozole, anastrazole, and letrozole for the treatment of HER2+/HR+ 
mBC patients in whom treatment with an aromatase inhibitor is suitable from a UK 
NHS perspective. METHODS: An area under the curve model based on the TAnDEM 
(trastuzumab/anastrozole vs. anastrozole) and EGF30008 (lapatinib/letrozole vs. letro-
zole) RCTs and the ﬁ ndings of a mixed treatment comparison (MTC) conducted on 
endocrine treatments in HR+ mBC was developed in Excel. a rank preserving structural 
failure time (RPSFT) model was utilized to account for the 70% crossover in TAnDEM. 
In the base-case, no attempt to account for the sizeable additional imbalance in 2nd line 
chemotherapy was made. The anastrozole PFS and RPSFT-adjusted OS curves from 
TAnDEM were utilized as a baseline from which to implement the required indirect 
comparisons under the assumption of an AI “class effect” (as suggested by expert clinical 
opinion and conﬁ rmed by the MTC). The present value of all costs and health outcomes 
attributable to each treatment option were calculated and the efﬁ ciency frontier deﬁ ned. 
Extensive deterministic and probabilistic sensitivity analyses were conducted. RESULTS: 
Anastrozole is dominated by letrozole. Lapatinib/letrozole is extendedly dominated by 
a combination of letrozole monotherapy and trastuzumab/anastrozole. Trastuzumab/
anastrozole produced the most QALYs of all regimens. Trastuzumab/anastrozole and 
letrozole deﬁ ne the efﬁ ciency frontier with a base-case ICER of £54,336/QALY. The 
use of the utility values derived from EGF30008 caused this ICER to fall to £44,497/
QALY. CONCLUSIONS: Lapatinib/letrozole is not a cost-effective use of ﬁ nite NHS 
resources at any cost-effectiveness threshold. As no attempt was made to account for 
the imbalance of 2nd line chemotherapy in TAnDEM (31% in anastrozole vs. 8% for 
trastuzumab/anastrozole) and relatively conservative utility values were used within 
the model the base-case ICER of trastuzumab/anastrozole vs. letrozole (£54,336/
QALY) should be regarded as conservative and the true ICER likely lies below 
£50,000/QALY gained.
